Key result
Levosimendan after PCI for acute MI fails to significantly improve LVEF versus control.
Why the study?
Levosimendan may improve myocardial recovery after PCI for acute myocardial infarction, but randomized evidence on its clinical effects compared with placebo or active inotropes remains uncertain.
Does levosimendan improve left ventricular ejection fraction and clinical outcomes compared to placebo or active inotropes in adults with acute myocardial infarction treated with percutaneous coronary intervention?
Meta-Analysis (n=662)
Does levosimendan improve left ventricular ejection fraction and clinical outcomes compared to placebo or active inotropes in adults with acute myocardial infarction treated with percutaneous coronary intervention?
In patients with acute myocardial infarction undergoing PCI, levosimendan did not significantly improve LVEF or mortality compared with placebo or active inotropes, with low to very low certainty of evidence.
Answers are grounded in this paper and cite their sources.
Does not support levosimendan for LVEF improvement after PCI in acute MI; confirms no significant benefit with low-certainty evidence.
Levosimendan may improve myocardial recovery after percutaneous coronary intervention (PCI) for acute myocardial infarction, but randomized evidence remains uncertain. We assessed clinical effects after PCI versus placebo or active inotropes. We searched PubMed, Scopus, Web of Science, Embase, and CENTRAL from inception through November 19, 2025, for randomized controlled trials of adults with acute myocardial infarction treated with PCI. Random-effects meta-analyses pooled mean differences (MDs) or risk ratios with 95% confidence intervals. Risk of bias was assessed using RoB 2, and certainty using GRADE. Nine randomized controlled trials reported in 11 publications enrolled 662 unique participants. Compared with control, levosimendan did not significantly improve left ventricular ejection fraction (5 studies; MD, 6.20 percentage points; 95% CI, -0.63 to 13.03; P = 0.065; I2 = 84.2%). The left ventricular ejection fraction estimate became significant after excluding one influential trial (MD, 8.11; 95% CI, 0.97-15.25), indicating sensitivity. Left ventricular end-diastolic volume index (2 studies) was lower with levosimendan (MD, -7.50 mL/m2; 95% CI, -14.94 to -0.05; P = 0.0497), but certainty was low. No significant differences were observed in left ventricular end-diastolic or end-systolic volume, wall motion score index, heart rate, cardiac index, mean arterial pressure, or all-cause mortality. Certainty was low or very low across all seven assessed GRADE outcomes.
No takes yet. Share an insight, caveat, or question.
Moubarak et al. (2026) conducted a meta-analysis in Acute myocardial infarction treated with percutaneous coronary intervention (n=662). Levosimendan vs. Placebo or active inotropes was evaluated on Left ventricular ejection fraction (MD 6.20 percentage points, 95% CI -0.63 to 13.03, p=0.065). Levosimendan after PCI for acute MI did not improve LVEF versus control.
Synapse has enriched 10 related papers. Consider them for comparative context: